U.S. Markets open in 1 hr 6 mins
  • S&P Futures

    3,789.50
    +27.25 (+0.72%)
     
  • Dow Futures

    30,927.00
    +207.00 (+0.67%)
     
  • Nasdaq Futures

    12,906.75
    +104.50 (+0.82%)
     
  • Russell 2000 Futures

    2,145.00
    +24.20 (+1.14%)
     
  • Crude Oil

    52.55
    +0.19 (+0.36%)
     
  • Gold

    1,834.20
    +4.30 (+0.23%)
     
  • Silver

    25.16
    +0.29 (+1.16%)
     
  • EUR/USD

    1.2133
    +0.0050 (+0.4125%)
     
  • 10-Yr Bond

    1.0970
    0.0000 (0.00%)
     
  • Vix

    22.89
    -0.36 (-1.55%)
     
  • GBP/USD

    1.3618
    +0.0031 (+0.2315%)
     
  • USD/JPY

    103.9480
    +0.2610 (+0.2517%)
     
  • BTC-USD

    37,009.42
    +567.68 (+1.56%)
     
  • CMC Crypto 200

    733.24
    -1.90 (-0.26%)
     
  • FTSE 100

    6,728.94
    +8.29 (+0.12%)
     
  • Nikkei 225

    28,633.46
    +391.25 (+1.39%)
     

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Neoleukin Therapeutics, Inc. (NLTX) Investigation

·2 min read

NEW YORK, NY / ACCESSWIRE / January 14, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neoleukin Therapeutics, Inc. ("Neoleukin" or the "Company") (NASDAQ:NLTX). Investors who purchased Neoleukin securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/nltx.

The investigation concerns whether Neoleukin and certain of its officers and/or directors have violated federal securities laws.

On January 8, 2021, Neoleukin announced that "on January 7, 2021, it received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug (IND) Application to begin a Phase 1 clinical program of its immunotherapeutic candidate, NL-201." Neoleukin disclosed that "[t]he FDA has informed Neoleukin that it needs to develop a new assay that more precisely measures the amount of protein being administered and demonstrate with this assay that dose and administration procedures will accurately deliver the intended dose of NL-201" and that "[t]he FDA also had additional requests not related to the clinical hold to be addressed by amendment of the IND." On this news, Neoleukin's stock price fell $1.73 per share, or 10.96%, to close at $14.05 per share on January 8, 2021.

If you are aware of any facts relating to this investigation, or purchased Neoleukin shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/nltx. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/624321/Bronstein-Gewirtz-Grossman-LLC-Notifies-Shareholders-of-Neoleukin-Therapeutics-Inc-NLTX-Investigation